HUE028642T2 - Preparations for incorporating biomolecules into cells - Google Patents

Preparations for incorporating biomolecules into cells Download PDF

Info

Publication number
HUE028642T2
HUE028642T2 HUE10767573A HUE10767573A HUE028642T2 HU E028642 T2 HUE028642 T2 HU E028642T2 HU E10767573 A HUE10767573 A HU E10767573A HU E10767573 A HUE10767573 A HU E10767573A HU E028642 T2 HUE028642 T2 HU E028642T2
Authority
HU
Hungary
Prior art keywords
peptide
protein
vitamin
biologically active
composition
Prior art date
Application number
HUE10767573A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Grandics
Susan Szathmary
Original Assignee
Galen Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Bio Inc filed Critical Galen Bio Inc
Publication of HUE028642T2 publication Critical patent/HUE028642T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE10767573A 2009-04-20 2010-04-19 Preparations for incorporating biomolecules into cells HUE028642T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17094509P 2009-04-20 2009-04-20

Publications (1)

Publication Number Publication Date
HUE028642T2 true HUE028642T2 (en) 2016-12-28

Family

ID=43011700

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10767573A HUE028642T2 (en) 2009-04-20 2010-04-19 Preparations for incorporating biomolecules into cells

Country Status (7)

Country Link
US (1) US11738084B2 (enExample)
EP (1) EP2421952B1 (enExample)
JP (2) JP6101077B2 (enExample)
KR (1) KR101742332B1 (enExample)
AU (1) AU2010239463B2 (enExample)
HU (1) HUE028642T2 (enExample)
WO (1) WO2010123798A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
JP6208767B2 (ja) * 2012-10-23 2017-10-04 エコール スペリュール デ フィジーク エ シミ アンドゥストリエル デ ラ ヴィル デ パリ 複数回逐次的に形成し、切断することができる可逆的共有結合を含む粒子
CN103849650B (zh) * 2013-10-14 2018-08-03 王深明 功能化纳米姜黄素的基因导入材料及制备方法
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
SG11201805375PA (en) 2016-02-04 2018-07-30 Stem Cell Theranostics Inc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CN108330102B (zh) * 2018-03-14 2020-02-14 江南大学 一株泰妙菌素单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954515A (enExample) 1972-10-03 1974-05-27
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
JP2524406B2 (ja) * 1988-07-05 1996-08-14 田辺製薬株式会社 パイロジェン定量方法
KR100191223B1 (ko) * 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
JPH10510433A (ja) 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6194469B1 (en) 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
ES2243229T3 (es) * 1999-02-03 2005-12-01 Powderject Res Ltd Formulaciones de particulas de hidrogel.
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
AU2001273128C1 (en) * 2000-06-29 2006-09-21 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
ES2263859T3 (es) * 2003-02-18 2006-12-16 Clinique La Prairie Research Sa Composiciones qu4e comprenden hemoglobina fetal y endotoxina bacteriana y opcionalmente componentes de higado fetal adicionales.
US7785769B2 (en) * 2003-07-25 2010-08-31 The United States of America as reprsented by the Secretary of the Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
CA2606349C (en) * 2005-01-28 2019-03-05 Galen Bio, Inc. Immunologically active compositions
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20070281036A1 (en) * 2005-12-19 2007-12-06 University Of Vermont And State Agricultural College System and method of delivering a desired material to a cell
US8288124B2 (en) * 2008-11-20 2012-10-16 Abbott Laboratories Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
ES2397909B1 (es) * 2011-05-05 2014-06-06 Universidad De Zaragoza Procedimiento de obtención de materiales multifuncionalizados

Also Published As

Publication number Publication date
EP2421952A2 (en) 2012-02-29
US11738084B2 (en) 2023-08-29
EP2421952B1 (en) 2016-03-30
JP6295235B2 (ja) 2018-03-14
KR20120109291A (ko) 2012-10-08
JP2016027048A (ja) 2016-02-18
JP6101077B2 (ja) 2017-03-22
KR101742332B1 (ko) 2017-05-31
WO2010123798A3 (en) 2011-03-10
AU2010239463B2 (en) 2016-12-08
AU2010239463A1 (en) 2011-12-08
JP2012524120A (ja) 2012-10-11
US20130095124A1 (en) 2013-04-18
CN102575225A (zh) 2012-07-11
WO2010123798A2 (en) 2010-10-28
EP2421952A4 (en) 2013-03-06

Similar Documents

Publication Publication Date Title
JP6295235B2 (ja) 生体分子を細胞へトランスフェクトするための組成物
JP6961061B2 (ja) 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ
US20230355689A1 (en) Solid dosage forms containing bacteria and microbial extracellular vesicles
US20220259254A1 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
KR102492850B1 (ko) 감염의 방지 그리고/또는 치료를 위한 방법과 시약
US20100297179A1 (en) Immunology Treatment for Biofilms
Gang Liu et al. Abrogation of cathepsin C by Helicobacter pylori impairs neutrophil activation to promote gastric infection
WO2020180801A1 (en) Plant-derived exosome-like nanoparticles inhibit bacterial pathogenicity
WO2022221183A1 (en) Fournierella extracellular vesicle preparations
US20240058271A1 (en) Extracellular vesicle preparations
CN102575225B (zh) 用于将生物分子转染进细胞的组合物
US20240423924A1 (en) Prevotella extracellular vesicle preparations
KR20240006543A (ko) 박테리아를 함유하는 약학적 조성물
WO2023114296A2 (en) Extracellular vesicle preparations
Yelyseyeva et al. Anti-adhesive therapies as a contemporary means to fight infectious diseases and adherence factors of Corynebacteria diphtheriae
US20240148797A1 (en) Compositions and methods for reducing cytokine expression
US20250049951A1 (en) Nucleic acid compositions and uses thereof
Cho et al. Bacterial DNA containing methylated CpG motifs retains immunostimulatory activity in synergy with modified lipopolysaccharides
WO2023114295A1 (en) Veillonella parvula bacteria extracellular vesicle preparations
WO2023114300A1 (en) Fournierella massiliensis bacteria extracellular vesicle preparations
Šmarda et al. The effects of some protein‐modifying reagents on the interaction of colicins A, E2, E3 and K with their respective Escherichia coli cell receptors
Wobser et al. A Novel Role for D-Alanylation of Lipoteichoic Acid of Enterococcus faecalis in Urinary Tract